Foundations of Hypersensitivity

Understanding Hypersensitivity Reactions What is Hypersensitivity? Hypersensitivity describes an immune response that damages tissue or causes significant harm to the body following exposure to an antigen. The key feature is that the immune reaction is excessive relative to the actual danger posed by the antigen. Unlike a protective immune response, a hypersensitivity reaction causes more damage than benefit. These reactions share an important characteristic: they're reproducible. When you're exposed to the same triggering antigen again, you'll experience a similar adverse reaction. This consistency helps distinguish hypersensitivity from other causes of tissue damage. Interestingly, the immune system can mount hypersensitivity reactions against many different targets: Harmless environmental substances (like pollen) Infectious pathogens (causing tissue damage beyond what the pathogen itself causes) The body's own tissues (self-antigens) The Gell and Coombs Classification Framework In 1963, Philip Gell and Robin Coombs developed a classification system that organizes hypersensitivity reactions into four types. This framework remains the standard in medical education and practice because it groups reactions by both the type of antigen and the immune mechanism driving the response. Understanding this classification is essential—it provides a mental map for recognizing different hypersensitivity patterns and predicting which clinical features will appear. Type I: Immediate Hypersensitivity Type I hypersensitivity is called "immediate" because symptoms appear within minutes to hours of antigen exposure. This is the classic allergic reaction. The Mechanism The process begins before any allergen exposure. During sensitization, B cells produce immunoglobulin E (IgE) antibodies specific to an allergen. These IgE antibodies then bind to high-affinity IgE receptors on the surfaces of mast cells and basophils—immune cells that are essentially waiting for this moment. The IgE stays bound to these cells, sometimes for months or years. When the allergen appears again, something critical happens: a single allergen molecule simultaneously binds to two nearby IgE molecules already attached to the mast cell surface. This cross-linking acts like a trigger signal that tells the mast cell "release your contents now." The mast cell and basophil then undergo degranulation—they rapidly release pre-packaged inflammatory mediators stored in their granules: Histamine: Causes itching, redness, swelling, and increased vascular permeability Leukotrienes: Cause bronchial constriction and increased mucus production Platelet-activating factor: Promotes blood clotting and platelet activation Tryptase: An enzyme that can activate complement These mediators flood local tissues, causing the familiar symptoms of allergies: itching, hives, swelling, and trouble breathing. Clinical Conditions Type I reactions cause many common conditions: Allergic rhinitis: "Hay fever" from pollen Food allergies: Reactions to peanuts, shellfish, tree nuts, etc. Urticaria and angioedema: Hives and swelling Anaphylaxis: The most severe form, with systemic symptoms including shock Venom allergies: Reactions to bee or wasp stings Drug allergies: Particularly to penicillin-type antibiotics A newer condition recognized as Type I is α-gal syndrome, where people develop IgE antibodies against a sugar found in mammalian meat, causing reactions to red meat. Type II: Cytotoxic Antibody-Mediated Hypersensitivity Type II reactions are fundamentally different from Type I: they involve IgG or IgM antibodies (not IgE) that recognize and attack specific cells or tissue structures. The Mechanism In Type II reactions, antibodies bind to antigens that are part of a cell's surface or embedded in tissue. Once the antibody attaches, several destructive pathways activate: Complement activation: The antibody binding triggers the classical complement pathway, leading to formation of the membrane attack complex, which literally punches holes in the target cell membrane, causing cell lysis (bursting). Opsonization and phagocytosis: The antibody coating makes the cell "look bad" to phagocytes (macrophages and neutrophils), which engulf and destroy the marked cell. Antibody-dependent cellular cytotoxicity (ADCC): Natural killer cells and other immune cells recognize the Fc portion of the bound antibody and kill the tagged cell. Anaphylatoxin release: Complement activation generates chemical signals (anaphylatoxins C3a and C5a) that recruit more immune cells to the scene. Clinical Conditions Type II reactions damage specific cell types or tissues: Hemolytic transfusion reactions: Antibodies against foreign red blood cells cause them to burst Hemolytic disease of the newborn: Maternal antibodies attack fetal red blood cells Autoimmune hemolytic anemia: The body makes antibodies against its own red blood cells Goodpasture syndrome: Antibodies attack the basement membrane in lungs and kidneys Graves' disease: Antibodies bind to thyroid-stimulating hormone receptors, actually activating thyroid cells to produce excess thyroid hormone Pemphigus: Antibodies attack cell adhesion molecules, causing the skin to blister and peel Notice that in Graves' disease, the antibody binding doesn't always mean cell destruction—sometimes the antibody instead activates the cell, demonstrating that Type II reactions can have various outcomes. Type III: Immune Complex-Mediated Hypersensitivity Type III reactions involve soluble antigen-antibody complexes that circulate in the bloodstream and deposit in tissues, causing inflammation. The Mechanism This reaction typically occurs when there's a large excess of antigen relative to antibody. The antigen and antibodies combine in the blood to form small immune complexes. Unlike well-matched antigen-antibody combinations that precipitate out of solution, these circulating complexes remain dissolved in the blood and travel throughout the body. These complexes eventually lodge in small blood vessels, joints, and filtering structures like the kidney glomeruli. Once deposited, the complexes trigger complement activation. This generates: Anaphylatoxins (C3a and C5a) that recruit neutrophils to the area Membrane attack complex that damages local tissue The arriving neutrophils release their enzymes and reactive oxygen species (free radicals), creating a local inflammatory fire. Blood vessels become inflamed (vasculitis), and surrounding tissues are damaged. The timing is important: Type III reactions typically appear 3-8 hours after exposure (or days for more chronic forms), distinguishing them from the immediate Type I reactions. Clinical Conditions Type III reactions cause: Serum sickness: Historically seen after administration of serum products (like antivenom) containing foreign proteins; now more common with certain drugs. Presents with fever, rash, and joint pain days after exposure. Post-streptococcal glomerulonephritis: After strep throat infection, immune complexes deposit in kidney filters, causing kidney damage and blood in urine Systemic lupus erythematosus (SLE): Chronic immune complex deposition throughout the body Rheumatoid arthritis: Immune complexes deposit in joints Acute hypersensitivity pneumonitis: Inhaled antigens (like from mold or bird feathers) form complexes in lung tissue, causing inflammation and breathing difficulty Type IV: Delayed-Type Hypersensitivity Type IV reactions are fundamentally different from the previous three types because they're mediated by T lymphocytes, not antibodies. They're called "delayed" because symptoms appear days after antigen exposure, not minutes or hours. The Mechanism When antigen is presented to T cells, specific T cell populations activate and release cytokines. The dominant players are: Helper T cells (Th1) that release interferon-gamma, activating macrophages Cytotoxic T lymphocytes (CTLs) that directly kill infected or altered cells Helper T cells (Th2) that recruit eosinophils Helper T cells (Th17) that recruit neutrophils These activated immune cells accumulate at the antigen site over days, creating intense local inflammation. The process is slower than Type I because it requires T cell activation and recruitment, rather than the pre-formed mediator release from mast cells. Type IV Subtypes Type IV is actually subdivided based on which T cells dominate: IVa (Th1-driven): Macrophage activation causes tissue damage. Example: tuberculin skin test IVb (Th2-driven): Eosinophil recruitment. Example: schistosomiasis IVc (CTL-driven): Direct killing of target cells. Example: drug-induced skin reactions IVd (Th17-driven): Neutrophil recruitment. Example: pustular drug eruptions Clinical Conditions Type IV reactions cause: Contact dermatitis: Rash appearing 48-72 hours after touching allergens like poison ivy, nickel, or latex Tuberculin skin test (Mantoux test): Induration appearing 48-72 hours after intradermal tuberculin injection Chronic hypersensitivity pneumonitis: Delayed lung inflammation from repeated antigen exposure Drug reactions: Including Stevens-Johnson syndrome and toxic epidermal necrolysis Transplant rejection: T cells attack foreign tissue Celiac disease: T cells respond to gluten proteins in the gut A practical way to remember Type IV: if you see an allergic reaction appearing days after exposure (not minutes), think Type IV. When One Disease Involves Multiple Types An important clinical reality is that a single disease can involve multiple hypersensitivity types simultaneously or sequentially. This complicates diagnosis and understanding but is crucial to recognize. Examples of Mixed Hypersensitivity Acute hypersensitivity pneumonitis begins as a Type III (immune complex) reaction when inhaled antigens from mold or bird feathers form complexes in lung tissue. However, the same disease can transition to a Type IV (delayed-type) component if exposure continues, with T cells becoming the dominant immune players. Allergic asthma shows this mixing in different airway locations. In the upper airways, Type I reactions (IgE-mediated) dominate, causing immediate swelling and mucus production. In the lower airways and lung tissue, Type IV (delayed-type) mechanisms with eosinophil and T cell involvement become more prominent, causing prolonged inflammation and airway remodeling. Atopic dermatitis typically begins with Type I mechanisms (IgE-mediated) but over time develops strong Type IV (T cell-mediated) components, creating a chronic inflammatory state that doesn't fully resolve even after the initial allergen is removed. This variability explains why some patients with allergic diseases respond well to antihistamines (blocking Type I mediators) while others don't—they may have significant Type IV involvement that isn't affected by antihistamine treatment. Clarifying Modern Terminology The terms "allergy" and "allergen" are sometimes used loosely in everyday language, so understanding precise definitions helps when reading medical literature and exam questions. Allergy in modern medical terminology means any hypersensitivity reaction mediated by an immunologic mechanism. This includes Type I, Type II, Type III, and Type IV reactions. Not all allergies involve IgE. Allergen specifically refers to an antigen that is bound by IgE antibodies. This is narrower than "antigen"—not every antigen that triggers an immune reaction is technically an allergen. This matters because you might see a question describing a Type IV delayed skin reaction to nickel, for example. In lay language, people might call this "a nickel allergy," and the nickel is the trigger. But technically, the nickel is not an allergen (because no IgE is involved), and calling it a "Type IV allergy" is using the broader definition of allergy that includes all hypersensitivity reactions, not just IgE-mediated ones.